Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 28, 2022, 12:40 p.m.

/zigman2/quotes/205619834/composite

$

156.77

Change

+8.15 +5.48%

Volume

Volume 4.03m

Real time quotes

/zigman2/quotes/205619834/composite

Previous close

$ 148.62

$ 156.77

Change

+8.15 +5.48%

Day low

Day high

$146.76

$159.87

Open

52 week low

52 week high

$117.34

$497.49

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

P/E Ratio (with extraordinary items)

9.13

Price to Sales Ratio

49.59

Price to Book Ratio

16.27

Price to Cash Flow Ratio

19.77

Enterprise Value to EBITDA

-76.36

Enterprise Value to Sales

4.72

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

617,996.00

Income Per Employee

-574,665.00

Receivables Turnover

1.13

Total Asset Turnover

0.18

Liquidity

Current Ratio

1.43

Quick Ratio

1.42

Cash Ratio

1.05

Profitability

Gross Margin

95.12

Operating Margin

-94.99

Pretax Margin

-92.67

Net Margin

-92.99

Return on Assets

-16.74

Return on Equity

-39.99

Return on Total Capital

-37.14

Return on Invested Capital

-36.66

Capital Structure

Total Debt to Total Equity

9.28

Total Debt to Total Capital

8.49

Total Debt to Total Assets

3.24

Long-Term Debt to Equity

8.09

Long-Term Debt to Total Capital

7.41

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 47 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 62 2020 Chief Financial Officer
Dr. Paul Burton - 2021 Chief Medical Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/24/2022 Stephen Hoge
President
223   Disposition at $157.69 per share. 35,164
01/24/2022 Stephen Hoge
President
100   Disposition at $155.87 per share. 15,587
01/24/2022 Stephen Hoge
President
100   Disposition at $154.83 per share. 15,483
01/24/2022 Stephen Hoge
President
700   Disposition at $154.04 per share. 107,828
01/24/2022 Stephen Hoge
President
10,772   Disposition at $153.32 per share. 1,651,563
01/24/2022 Stephen Hoge
President
600   Disposition at $152.08 per share. 91,248
01/24/2022 Stephen Hoge
President
900   Disposition at $150.79 per share. 135,711
01/24/2022 Stephen Hoge
President
1,161   Disposition at $149.41 per share. 173,465
01/24/2022 Stephen Hoge
President
900   Disposition at $148.65 per share. 133,785
01/24/2022 Stephen Hoge
President
800   Disposition at $147.24 per share. 117,792
01/24/2022 Stephen Hoge
President
600   Disposition at $145.83 per share. 87,498
01/24/2022 Stephen Hoge
President
1,200   Disposition at $144.67 per share. 173,604
01/24/2022 Stephen Hoge
President
500   Disposition at $143.55 per share. 71,775
01/24/2022 Stephen Hoge
President
395   Disposition at $142.54 per share. 56,303
01/24/2022 Stephen Hoge
President
350   Disposition at $141.48 per share. 49,518
01/24/2022 Stephen Hoge
President
699   Disposition at $138.95 per share. 97,126
01/24/2022 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
01/24/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
01/24/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
01/20/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $175.01 per share. 1,750,100
01/19/2022 Stéphane Bancel
Chief Executive Officer; Director
4,000   Gift at $0 per share. 0
01/19/2022 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $188.55 per share. 1,696,950
01/13/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $219.56 per share. 2,195,600
01/13/2022 Stephen Hoge
President
15,000   Disposition at $219.56 per share. 3,293,400
01/13/2022 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
01/13/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
01/12/2022 Stéphane Bancel
Chief Executive Officer; Director
4,000   Gift at $0 per share. 0
01/12/2022 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $220.01 per share. 1,980,090
01/12/2022 Stephen Hoge
President
5,000   Disposition at $220.01 per share. 1,100,050
01/12/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
01/06/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $215.33 per share. 2,153,300
01/05/2022 Stéphane Bancel
Chief Executive Officer; Director
4,000   Gift at $0 per share. 0
01/05/2022 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $232.1 per share. 2,088,900
01/03/2022 Stephen Hoge
President
20,000   Disposition at $247.08 per share. 4,941,600
01/03/2022 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
01/03/2022 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
12/31/2021 Juan Andres
See remarks
5,000   Disposition at $249.88 per share. 1,249,400
12/31/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
12/30/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $243.42 per share. 2,434,200
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. Moderna’s Stock Has Slumped. Its Future Looks Bright.

    10:50 a.m. Today

    - Josh Nathan-Kazis

  2. Moderna Inc. stock underperforms Thursday when compared to competitors

    4:31 p.m. Jan. 27, 2022

    - MarketWatch Automation

  3. Moderna begins testing omicron-specific COVID-19 vaccine in adults

    5:39 p.m. Jan. 26, 2022

    - Associated Press

  4. Moderna Starts Testing Its Own Omicron-Specific Booster

    5:05 p.m. Jan. 26, 2022

    - Josh Nathan-Kazis

  5. Moderna Inc. stock rises Wednesday, outperforms market

    4:31 p.m. Jan. 26, 2022

    - MarketWatch Automation

  6. Powell Spooks Markets. Stocks End in the Red.

    4:19 p.m. Jan. 26, 2022

    - Jacob Sonenshine

  7. Covid-19 Deaths in U.S. Hit Highest Level in Nearly a Year

    9:01 a.m. Jan. 26, 2022

    - Lina Saigol

  8. Moderna stock price target cut to $175 from $200 at Deutsche Bank

    6:53 a.m. Jan. 26, 2022

    - Tomi Kilgore

  9. Moderna upgraded to hold from sell at Deutsche Bank

    6:53 a.m. Jan. 26, 2022

    - Tomi Kilgore

  10. Moderna Inc. stock falls Tuesday, underperforms market

    4:31 p.m. Jan. 25, 2022

    - MarketWatch Automation

  11. 10 Cheap Stocks for Volatile Markets

    8:18 a.m. Jan. 25, 2022

    - Andrew Bary

  12. These stocks in the S&P 500 had price swings of 10% or more Monday

    6:08 a.m. Jan. 25, 2022

    - Philip van Doorn

  13. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. Want Extra Income? Get Paid by These 2 Healthcare Dividend Stocks in 2022

    11:30 a.m. Today

    - Motley Fool

  2. Novavax Marches Ahead With Several Positive, Major Developments

    9:49 a.m. Today

    - Seeking Alpha

  3. Why Novavax Stock Is Sinking Again This Week

    5:33 p.m. Jan. 27, 2022

    - Motley Fool

  4. 1 Top Biotech Stock Ready for a Bull Run

    7:21 a.m. Jan. 27, 2022

    - Motley Fool

  5. Could Vaxart's Vaccine Pill Help to End the Pandemic?

    6:33 a.m. Jan. 27, 2022

    - Motley Fool

  6. Moderna Starts Testing Omicron Vaccine in People

    5:05 p.m. Jan. 26, 2022

    - Peter Loftus

  7. Why Coronavirus Vaccine Stocks Topped the Market Today

    4:49 p.m. Jan. 26, 2022

    - Motley Fool

  8. LABU - A Compelling Biotech Trade

    4:24 p.m. Jan. 26, 2022

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2021

Revenue

$803.40M

Net Income

$-747.06M

2020 Sales Growth

1234.3%

Employees

1,300

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. Nasdaq 100 Movers: LRCX, MRNA

    10:30 a.m. Jan. 25, 2022

    - MarketNewsVideo.com

  2. S&P 500 Movers: GE, AXP

    10:18 a.m. Jan. 25, 2022

    - MarketNewsVideo.com

  3. Moderna Inc. Common Stock (MRNA) Trading Report

    3:42 p.m. Jan. 20, 2022

    - Stock Traders Daily

  4. Nasdaq 100 Movers: PTON, ATVI

    10:26 a.m. Jan. 18, 2022

    - MarketNewsVideo.com

  5. Nasdaq 100 Movers: MRNA, LRCX

    11:03 a.m. Jan. 13, 2022

    - MarketNewsVideo.com

  6. Nasdaq 100 Movers: MRNA, ILMN

    11:23 a.m. Jan. 11, 2022

    - MarketNewsVideo.com

  7. S&P 500 Movers: IBM, ILMN

    11:22 a.m. Jan. 11, 2022

    - MarketNewsVideo.com

  8. Moderna Inc. Common Stock MRNA Proactive Strategies

    9:43 p.m. Jan. 10, 2022

    - Stock Traders Daily

  9. Monday's ETF Movers: BBH, ARKF

    12:47 p.m. Jan. 10, 2022

    - MarketNewsVideo.com

  10. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.